What question did this study set out to answer?

This research investigates the pharmacokinetics and bioavailability of a novel curcumin formulation (BNT–C060) compared to free curcumin.

June 3, 2026Scientific ReportsOpen Access

Enhanced bioavailability of a novel double-layered nano-liposomal curcumin (BNT–C060): a randomized, double-blind, clinical trial

View Full Paper

Ask AI

Bookmark

This research investigates the pharmacokinetics and bioavailability of a novel curcumin formulation (BNT–C060) compared to free curcumin.
Randomized, double-blind, parallel-group trial
Eighteen healthy males (n=9/group) received either BNT–C060 (400 mg) or free curcumin (2,000 mg)
Plasma and urine samples collected over 24 hours for curcumin analysis (LC–MS/MS)
BNT–C060 demonstrated 23.2-fold higher plasma AUC 0–t (5.00 vs. 0.22 ng·h/mL/mg)
BNT–C060 achieved 53-fold higher C max (1.06 vs. 0.02 ng/mL/mg) and 35.3-fold higher urinary exposure
BNT–C060 was generally well tolerated with no significant safety issues observed

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates enhanced bioavailability of BNT–C060 in healthy males, suggesting improved systemic absorption.

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark